FlavoLife
FlavoLife develops senolytic drugs and medical foods designed to selectively clear stress-induced senescent cells that accumulate during premature ageing. The company's drug candidates are engineered as pan-senolytics targeting diverse senescent cell populations, while its medical food platform specifically addresses chemotherapy-induced cellular senescence to reduce treatment toxicity. FlavoLife aims to advance preclinical development toward treatments for age-related conditions with significant medical need.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
Funding
Founders
Product
Problem
Stress-induced senescent cells accumulate throughout the body during premature ageing, driving tissue dysfunction and chronic inflammation. Additionally, most chemotherapies induce cellular senescence that persists in tissues, worsening treatment side effects and contributing to long-term toxicity in cancer patients.
Solution
FlavoLife develops senolytic drugs and medical foods designed to selectively clear stress-induced senescent cells. Its drug candidates are engineered as pan-senolytics, targeting a broad and diverse range of senescent cells accumulating across the body, with a focus on achieving high efficacy and an excellent safety profile. The company has also developed the first platform of innovative senolytic medical foods specifically for cancer patients, addressing chemotherapy-induced senescence to reduce local and systemic inflammation. These dual pathways aim to lift the burden of accelerated ageing while laying groundwork for treatments in areas of significant medical need.
Target Audience
Primary customers are clinical researchers and healthcare providers focused on age-related disease and oncology supportive care, as well as cancer patients seeking to reduce chemotherapy toxicity through medical food interventions.
Features
- Pan-senolytic drug candidates designed to target broad and diverse senescent cell populations throughout the body
- Drug engineering focused on high efficacy combined with an excellent safety profile for preclinical advancement
- First senolytic medical food platform developed specifically for cancer patients undergoing chemotherapy
- Medical foods target chemotherapy-induced senescent cells to reduce local and systemic inflammation
- Dual product pipeline spanning both pharmaceutical drug development and regulated medical food categories